References

Aithal, G. P., Ramsay, L., Daly, A. K., Sonchit, N., Leathart, J. B., Alexander, G., Kenna, J. G., Caldwell, J., and Day, C. P. (2004). Hepatic adducts, circulating antibodies, and cytokine polymorphisms in patients with diclofenac hepatotoxicity. Hepatology 39, 1430-40.

Andrade, R. J., Lucena, M. I., Alonso, A., Garcia-Cortes, M., Garcia-Ruiz, E., Benitez, R., Fernandez, M. C., Pelaez, G., Romero, M., Corpas, R., Duran, J. A., Jimenez, M., Rodrigo, L., Nogueras, F., Martin-Vivaldi, R., Navarro, J. M., Salmeron, J., de la Cuesta, F. S., and Hidalgo, R. (2004). HLA class II genotype influences the type of liver injury in drug-induced idiosyncratic liver disease. Hepatology 39, 1603-12.

Beaune, P., Dansette, P. M., Mansuy, D., Kiffel, L., Finck, M., Amar, C., Leroux, J. P., and Homberg, J. C. (1987). Human anti-endoplasmic reticulum autoantibodies appearing in a drug-induced hepatitis are directed against a human liver cytochrome P-450 that hydroxylates the drug. Proc Natl Acad Sci USA 84, 551-5.

Bedard, K., Smith, S., and Cribb, A. (2000). Sequential assessment of an antidrug antibody response in a patient with a systemic delayed-onset sulphonamide hypersensitivity syndrome reaction. Br J Dermatol 142, 253-8.

Boelsterli, U. A. (2003). Diclofenac-induced liver injury: a paradigm of idiosyncratic drug toxicity. Toxicol Appl Pharmacol 192, 307-22.

Bolze, S., Bromet, N., Gay-Feutry, C., Massiere, F., Boulieu, R., and Hulot, T. (2002). Development of an in vitro screening model for the biosynthesis of acyl glucuronide metabolites and the assessment of their reactivity toward human serum albumin. Drug Metab Dispos 30, 404-13.

Bourdi, M., Chen, W., Peter, R. M., Martin, J. L., Buters, J. T., Nelson, S. D., and Pohl, L. R. (1996). Human cytochrome P450 2E1 is a major autoantigen associated with halothane hepatitis. Chem Res Toxicol 9, 1159-66.

Bourdi, M., Larrey, D., Nataf, J., Bernuau, J., Pessayre, D., Iwasaki, M., Guengerich, F. P., and Beaune, P. H. (1990). Anti-liver endoplasmic reticulum autoantibodies are directed against human cytochrome P-450IA2. A specific marker of dihydralazine-induced hepatitis. J Clin Invest 85, 1967-73.

Castillo, M., and Smith, P. C. (1995). Disposition and reactivity of ibuprofen and ibufenac acyl glucuronides in vivo in the rhesus monkey and in vitro with human serum albumin. Drug Metab Dispos 23, 566-72.

Christ, D. D., Satoh, H., Kenna, J. G., and Pohl, L. R. (1988). Potential metabolic basis for enflurane hepatitis and the apparent cross-sensitization between enflurane and halothane. Drug Metab Dispos 16, 135-40.

Clarke, J. B., Maggs, J. L., Kitteringham, N. R., and Park, B. K. (1990). Immunogenicity of amodiaquine in the rat. Int Arch Allergy Appl Immunol 91, 335-42.

Clarke, J. B., Neftel, K., Kitteringham, N. R., and Park, B. K. (1991). Detection of antidrug IgG antibodies in patients with adverse drug reactions to amodiaquine.

Int Arch Allergy Appl Immunol 95, 369-75.

Cohen, S. D., and Khairallah, E. A. (1997). Selective protein arylation and acetaminophen-induced hepatotoxicity. Drug Metab Rev 29, 59-77.

Cohen, S. D., Pumford, N. R., Khairallah, E. A., Boekelheide, K., Pohl, L. R., Amouzadeh, H. R., and Hinson, J. A. (1997). Selective protein covalent binding and target organ toxicity. Toxicol Appl Pharmacol 143, 1-12.

Corzo, D., Yunis, J. J., Salazar, M., Lieberman, J. A., Howard, A., Awdeh, Z., Alper, C. A., and Yunis, E. J. (1995). The major histocompatibility complex region marked by HSP70-1 and HSP70-2 variants is associated with clozapine-induced agranulocytosis in two different ethnic groups. Blood 86, 3835-40.

Cribb, A. E., Lee, B. L., Trepanier, L. A., and Spielberg, S. P. (1996). Adverse reactions to sulphonamide and sulphonamide-trimethoprim antimicrobials: clinical syndromes and pathogenesis. Adverse Drug React Toxicol Rev 15, 9-50.

Cribb, A. E., Nuss, C. E., Alberts, D. W., Lamphere, D. B., Grant, D. M., Grossman, S. J., and Spielberg, S. P. (1996). Covalent binding of sulfamethoxazole reactive metabolites to human and rat liver subcellular fractions assessed by immunochemical detection. Chem Res Toxicol 9, 500-7.

Cribb, A. E., Pohl, L. R., Spielberg, S. P., and Leeder, J. S. (1997). Patients with delayed-onset sulfonamide hypersensitivity reactions have antibodies recognizing endoplasmic reticulum luminal proteins. J Pharmacol Exp Ther 282, 1064-71.

De Berardinis, V, Moulis, C., Maurice, M., Beaune, P., Pessayre, D., Pompon, D., and Loeper, J. (2000). Human microsomal epoxide hydrolase is the target of germander-induced autoantibodies on the surface of human hepatocytes. Mol

Pharmacol 58, 542-51.

Dettling, M., Schaub, R. T., Mueller-Oerlinghausen, B., Roots, I., and Cascorbi, I. (2001). Further evidence of human leukocyte antigen-encoded susceptibility to clozapine-induced agranulocytosis independent of ancestry. Pharmacogenetics 11, 135-41.

Eliasson, E., and Kenna, J. G. (1996). Cytochrome P450 2E1 is a cell surface autoantigen in halothane hepatitis. Mol Pharmacol 50, 573-82.

Engler, O. B., Strasser, I., Naisbitt, D. J., Cerny, A., and Pichler, W. J. (2004). A chemically inert drug can stimulate T cells in vitro by their T cell receptor in non-sensitised individuals. Toxicology 197, 47-56.

Evans, D. C., Watt, A. P., Nicoll-Griffith, D. A., and Baillie, T. A. (2004). Drug-protein adducts: an industry perspective on minimizing the potential for drug bioactivation in drug discovery and development. Chem Res Toxicol 17, 3-16.

Evans, W. E. (2004). Pharmacogenetics of thiopurine S-methyltransferase and thiopurine therapy. Ther Drug Monit 26, 186-91.

Farrell, G. C. (2002). Drugs and steatohepatitis. Semin Liver Dis 22, 185-94.

Freeman, R. W., Uetrecht, J. P., Woosley, R. L., Oates, J. A., and Harbison, R. D. (1981). Covalent binding of procainamide in vitro and in vivo to hepatic protein in mice. Drug Metab Dispos 9, 188-92.

Furst, S. M., Luedke, D., Gaw, H. H., Reich, R., and Gandolfi, A. J. (1997). Demonstration of a cellular immune response in halothane-exposed guinea pigs. Toxicol Appl Pharmacol 143, 245-55.

Gardner, I., Leeder, J. S., Chin, T., Zahid, N., and Uetrecht, J. P. (1998). A comparison of the covalent binding of clozapine and olanzapine to human neutrophils in vitro and in vivo. Mol Pharmacol 53, 999-1008.

Gardner, I., Zahid, N., MacCrimmon, D., and Uetrecht, J. P. (1998). A comparison of the oxidation of clozapine and olanzapine to reactive metabolites and the toxicity of these metabolites to human leukocytes. Mol Pharmacol 53, 991-8.

Gibson, J. D., Pumford, N. R., Samokyszyn, V M., and Hinson, J. A. (1996). Mechanism of acetaminophen-induced hepatotoxicity: covalent binding versus oxidative stress. Chem Res Toxicol 9, 580-5.

Gut, J., Christen, U., and Huwyler, J. (1993). Mechanisms of halothane toxicity: novel insights. Pharmacol Ther 58, 133-55.

Hastings, K. L., Thomas, C., Brown, A. P., and Gandolfi, A. J. (1995). Trifluoroacetylation potentiates the humoral immune response to halothane in the guinea pig. Immunopharmacol Immunotoxicol 17, 201-13.

Kearns, G. L., Wheeler, J. G., Childress, S. H., and Letzig, L. G. (1994). Serum sickness-like reactions to cefaclor: role of hepatic metabolism and individual susceptibility. J Pediatr 125, 805-11.

Kenna, J. G., Neuberger, J., and Williams, R. (1987). Identification by immunoblotting of three halothane-induced liver microsomal polypeptide antigens recognized by antibodies in sera from patients with halothane-associated hepatitis. J Pharmacol Exp Ther 242, 733-40.

Kenna, J. G., Neuberger, J., and Williams, R. (1988). Evidence for expression in human liver of halothane-induced neoantigens recognized by antibodies in sera from patients with halothane hepatitis. Hepatology 8, 1635-41.

Knight, T. L., Scatchard, K. M., Van Pelt, F. N., and Kenna, J. G. (1994). Sera from patients with halothane hepatitis contain antibodies to halothane-induced liver antigens which are not detectable by immunoblotting. J Pharmacol Exp Ther 270, 1325-33.

Kretz-Rommel, A., and Boelsterli, U. A. (1993). Diclofenac covalent protein binding is dependent on acyl glucuronide formation and is inversely related to P450-mediated acute cell injury in cultured rat hepatocytes. Toxicol Appl Pharmacol 120, 155-61.

Kretz-Rommel, A., and Boelsterli, U. A. (1994). Selective protein adducts to membrane proteins in cultured rat hepatocytes exposed to diclofenac: radiochemical and immunochemical analysis. Mol Pharmacol 45, 237-44.

Kretz-Rommel, A., and Boelsterli, U. A. (1995). Cytotoxic activity of T cells and non-T cells from diclofenac-immunized mice against cultured syngeneic hepatocytes exposed to diclofenac. Hepatology 22, 213-22.

Larrey, D., Berson, A., Habersetzer, F., Tinel, M., Castot, A., Babany, G., Letteron, P., Freneaux, E., Loeper, J., and Dansette, P. (1989). Genetic predisposition to drug hepatotoxicity: role in hepatitis caused by amineptine, a tricyclic antidepressant. Hepatology 10, 168-73.

Lecoeur, S., Andre, C., and Beaune, P. H. (1996). Tienilic acid-induced autoimmune hepatitis: anti-liver and-kidney microsomal type 2 autoantibodies recognize a three-site conformational epitope on cytochrome P4502C9. Mol

Pharmacol 50, 326-33.

Lecoeur, S., Bonierbale, E., Challine, D., Gautier, J. C., Valadon, P., Dansette, P. M., Catinot, R., Ballet, F., Mansuy, D., and Beaune, P. H. (1994). Specificity of in vitro covalent binding of tienilic acid metabolites to human liver microsomes in relationship to the type of hepatotoxicity: comparison with two directly hepatotoxic drugs. Chem Res Toxicol 7, 434-42.

Lennard, L., Van Loon, J. A., and Weinshilboum, R. M. (1989). Pharmacogenetics of acute azathioprine toxicity: relationship to thiopurine methyltransferase genetic polymorphism. Clin Pharmacol Ther 46, 149-54.

Loeper, J., De Berardinis, V., Moulis, C., Beaune, P., Pessayre, D., and Pompon, D. (2001). Human epoxide hydrolase is the target of germander autoantibodies on the surface of human hepatocytes: enzymatic implications. Adv Exp Med Biol 500, 121-4.

Mallal, S., Nolan, D., Witt, C., Masel, G., Martin, A. M., Moore, C., Sayer, D., Castley, A., Mamotte, C., Maxwell, D., James, I., and Christiansen, F. T. (2002). Association between presence of HLA-B*5701, HLA-DR7, and HLA-DQ3 and hypersensitivity to HIV-1 reverse-transcriptase inhibitor abacavir. Lancet 359, 727-32.

Manchanda, T., Hess, D., Dale, L., Ferguson, S. G., and Rieder, M. J. (2002). Haptenation of sulfonamide reactive metabolites to cellular proteins. Mol

Pharmacol 62, 1011-26.

Martin, A. M., Nolan, D., Gaudieri, S., Almeida, C. A., Nolan, R., James, I., Carvalho, F., Phillips, E., Christiansen, F. T., Purcell, A. W., McCluskey, J., and Mallal, S. (2004). Predisposition to abacavir hypersensitivity conferred by HLA-B*5701 and a haplotypic Hsp70-Hom variant. Proc Natl Acad Sci USA 101, 41805.

Matzinger, P. (2002). The danger model: a renewed sense of self. Science 296, 3015.

Mieli-Vergani, G., Vergani, D., Tredger, J. M., Eddleston, A. L., Davis, M., and Williams, R. (1980). Lymphocyte cytotoxicity to halothane altered hepatocytes in patients with severe hepatic necrosis following halothane anaesthesia. J Clin

Lab Immunol 4, 49-51.

Naisbitt, D. J., Farrell, J., Gordon, S. F., Maggs, J. L., Burkhart, C., Pichler, W. J., Pirmohamed, M., and Park, B. K. (2002). Covalent binding of the nitroso metabolite of sulfamethoxazole leads to toxicity and major histocompatibility complex-restricted antigen presentation. Mol Pharmacol 62, 628-37.

Neuberger, J., and Williams, R. (1989). Immune mechanisms in tienilic acid associated hepatotoxicity. Gut 30, 515-9.

Park, B. K., Coleman, J. W., and Kitteringham, N. R. (1987). Drug disposition and drug hypersensitivity. Biochem Pharmacol 36, 581-90.

Park, B. K., Naisbitt, D. J., Gordon, S. F., Kitteringham, N. R., and Pirmohamed, M. (2001). Metabolic activation in drug allergies. Toxicology 158, 11-23.

Pirmohamed, M., Lin, K., Chadwick, D., and Park, B. K. (2001). TNFalpha promoter region gene polymorphisms in carbamazepine-hypersensitive patients. Neurology 56, 890-6.

Pirmohamed, M., Naisbitt, D. J., Gordon, F., and Park, B. K. (2002). The danger hypothesis-potential role in idiosyncratic drug reactions. Toxicology 181-182, 5563.

Pons, C., Dansette, P. M., Amar, C., Jaouen, M., Wolf, C. R., Gregeois, J., Homberg, J. C., and Mansuy, D. (1991). Detection of human hepatitis anti-liver kidney microsomes (LKM2) autoantibodies on rat liver sections is predominantly due to reactivity with rat liver P-450 IIC11. J Pharmacol Exp Ther 259, 1328-34.

Pumford, N. R., Halmes, N. C., and Hinson, J. A. (1997a). Covalent binding of xenobiotics to specific proteins in the liver. Drug Metab Rev 29, 39-57.

Pumford, N. R., Halmes, N. C., Martin, B. M., Cook, R. J., Wagner, C., and Hinson, J. A. (1997b). Covalent binding of acetaminophen to N-10-formyltetrahydrofolate dehydrogenase in mice. J Pharmacol Exp Ther 280, 5015.

Reilly, T. P., Lash, L. H., Doll, M. A., Hein, D. W., Woster, P. M., and Svensson, C. K. (2000). A role for bioactivation and covalent binding within epidermal keratinocytes in sulfonamide-induced cutaneous drug reactions. J Invest Dermatol 114, 1164-73.

Rieder, M. J., Shear, N. H., Kanee, A., Tang, B. K., and Spielberg, S. P. (1991). Prominence of slow acetylator phenotype among patients with sulfonamide hypersensitivity reactions. Clin Pharmacol Ther 49, 13-7.

Rieder, M. J., Uetrecht, J., Shear, N. H., Cannon, M., Miller, M., and Spielberg, S. P. (1989). Diagnosis of sulfonamide hypersensitivity reactions by in-vitro "rechallenge" with hydroxylamine metabolites. Ann Intern Med 110, 286-9.

Riley, R. J., and Leeder, J. S. (1995). In vitro analysis of metabolic predisposition to drug hypersensitivity reactions. Clin Exp Immunol 99, 1-6.

Riley, R. J., Maggs, J. L., Lambert, C., Kitteringham, N. R., and Park, B. K. (1988). An in vitro study of the microsomal metabolism and cellular toxicity of phenytoin, sorbinil and mianserin. Br J Clin Pharmacol 26, 577-88.

Riley, R. J., Smith, G., Wolf, C. R., Cook, V A., and Leeder, J. S. (1993). Human anti-endoplasmic reticulum autoantibodies produced in aromatic anticonvulsant hypersensitivity reactions recognise rodent CYP3A proteins and a similarly regulated human P450 enzyme(s). Biochem Biophys Res Commun 191, 32-40.

Roberts, S. A., Price, V. F., and Jollow, D. J. (1990). Acetaminophen structure -toxicity studies: in vivo covalent binding of a nonhepatotoxic analog, 3-hydroxyacetanilide. Toxicol Appl Pharmacol 105, 195-208.

Roujeau, J. C., Huynh, T. N., Bracq, C., Guillaume, J. C., Revuz, J., and Touraine, R. (1987). Genetic susceptibility to toxic epidermal necrolysis. Arch Dermatol 123, 1171-3.

Schnyder, B., Burkhart, C., Schnyder-Frutig, K., von Greyerz, S., Naisbitt, D. J., Pirmohamed, M., Park, B. K., and Pichler, W. J. (2000). Recognition of sulfamethoxazole and its reactive metabolites by drug-specific CD4+ T cells from allergic individuals. J Immunol 164, 6647-54.

Shear, N. H., and Spielberg, S. P. (1988). Anticonvulsant hypersensitivity syndrome. In vitro assessment of risk. J Clin Invest 82, 1826-32.

Shear, N. H., Spielberg, S. P., Grant, D. M., Tang, B. K., and Kalow, W. (1986). Differences in metabolism of sulfonamides predisposing to idiosyncratic toxicity.

Ann Intern Med 105, 179-84.

Stravitz, R. T., and Sanyal, A. J. (2003). Drug-induced steatohepatitis. Clin Liver Dis 7, 435-51.

Summan, M., and Cribb, A. E. (2002). Novel non-labile covalent binding of sulfamethoxazole reactive metabolites to cultured human lymphoid cells. Chem

Biol Interact 142, 155-73.

Uetrecht, J. (2003). Screening for the potential of a drug candidate to cause idiosyncratic drug reactions. Drug Discov Today 8, 832-7.

Uetrecht, J. P. (1999). New concepts in immunology relevant to idiosyncratic drug reactions: the "danger hypothesis" and innate immune system. Chem Res Toxicol 12, 387-95.

Vergani, D., Mieli-Vergani, G., Alberti, A., Neuberger, J., Eddleston, A. L., Davis, M., and Williams, R. (1980). Antibodies to the surface of halothane-altered rabbit hepatocytes in patients with severe halothane-associated hepatitis. N Engl

Wade, L. T., Kenna, J. G., and Caldwell, J. (1997). Immunochemical identification of mouse hepatic protein adducts derived from the nonsteroidal anti-inflammatory drugs diclofenac, sulindac, and ibuprofen. Chem Res Toxicol 10, 546-55.

Williams, D. P., and Park, B. K. (2003). Idiosyncratic toxicity: the role of toxicophores and bioactivation. Drug Discov Today 8, 1044-50.

Yunis, J. J., Lieberman, J., and Yunis, E. J. (1992). Major histocompatibility complex associations with clozapine-induced agranulocytosis. The USA experience. Drug Saf 7 Suppl 1, 7-9.

51 Ways to Reduce Allergies

51 Ways to Reduce Allergies

Do you hate the spring? Do you run at the site of a dog or cat? Do you carry around tissues wherever you go? Youre not alone. 51 Ways to Reduce Allergies can help. Find all these tips and more Start putting those tissues away. Get Your Copy Of 51 Ways to Reduce Allergies Today.

Get My Free Ebook


Post a comment